Kiniksa announces positive results for mavrilimumab in phase 2 portion of phase 2/3 trial in non-mechanically ventilated severe covid-19 patients

Study of this investigational monoclonal antibody that targets GMCSF receptor alpha met primary endpoint of proportion of patients alive and free of mechanical ventilation at day 29 (12.3% higher with mavrilimumab vs. placebo; 86.7 vs. 74.4%).

Biospace Inc.